These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37671164)

  • 1. Strategies for enhancing CAR T cell expansion and persistence in HIV infection.
    Rothemejer FH; Lauritsen NP; Søgaard OS; Tolstrup M
    Front Immunol; 2023; 14():1253395. PubMed ID: 37671164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.
    Rust BJ; Kean LS; Colonna L; Brandenstein KE; Poole NH; Obenza W; Enstrom MR; Maldini CR; Ellis GI; Fennessey CM; Huang ML; Keele BF; Jerome KR; Riley JL; Kiem HP; Peterson CW
    Blood; 2020 Oct; 136(15):1722-1734. PubMed ID: 32614969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
    Ollerton MT; Berger EA; Connick E; Burton GF
    J Virol; 2020 May; 94(10):. PubMed ID: 32161179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
    Katsarou A; Sjöstrand M; Naik J; Mansilla-Soto J; Kefala D; Kladis G; Nianias A; Ruiter R; Poels R; Sarkar I; Patankar YR; Merino E; Reijmers RM; Frerichs KA; Yuan H; de Bruijn J; Stroopinsky D; Avigan D; van de Donk NWCJ; Zweegman S; Mutis T; Sadelain M; Groen RWJ; Themeli M
    Sci Transl Med; 2021 Dec; 13(623):eabh1962. PubMed ID: 34878825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust CAR-T memory formation and function via hematopoietic stem cell delivery.
    Zhen A; Carrillo MA; Mu W; Rezek V; Martin H; Hamid P; Chen ISY; Yang OO; Zack JA; Kitchen SG
    PLoS Pathog; 2021 Apr; 17(4):e1009404. PubMed ID: 33793675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
    Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
    Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.
    Zhao Z; Chen Y; Francisco NM; Zhang Y; Wu M
    Acta Pharm Sin B; 2018 Jul; 8(4):539-551. PubMed ID: 30109179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
    Wei W; Chen ZN; Wang K
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies.
    Buck AM; Deveau TM; Henrich TJ; Deitchman AN
    Viruses; 2023 May; 15(5):. PubMed ID: 37243212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
    MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
    Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
    Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.
    Zhen A; Peterson CW; Carrillo MA; Reddy SS; Youn CS; Lam BB; Chang NY; Martin HA; Rick JW; Kim J; Neel NC; Rezek VK; Kamata M; Chen ISY; Zack JA; Kiem HP; Kitchen SG
    PLoS Pathog; 2017 Dec; 13(12):e1006753. PubMed ID: 29284044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies.
    Watanabe K; Nishikawa H
    Int Immunol; 2021 Oct; 33(11):551-562. PubMed ID: 34374779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.